HistoSonics Selected as One of the Hottest Startups at the 2019 J.P. Morgan Healthcare Investment Conference
Non-Invasive Surgical Robotics Company with "Pure Sci-Fi" Technology Joins The Observer's List of Top Firms
ANN ARBOR, Mich., Jan. 7, 2019 /PRNewswire/ -- HistoSonics, a privately-held company developing a non-invasive robotics platform for treating disease, has been named by The Observer as one of the nation's hottest medical technology companies. The list, released today, highlights an array of digital health and medical technology startups that are revolutionizing their respective fields. The list was published just as the 37th Annual J.P. Morgan Healthcare Investment Conference is kicking off in San Francisco, where venture capitalists and health industry experts surveyed by The Observer believe HistoSonics will be among the most in-demand companies in attendance.
The article described HistoSonics as follows:
HistoSonics is the stuff of pure sci-fi. The start-up from the Wolverine State has developed a completely non-invasive robotics platform and new procedure, Robotically Assisted Sonic Therapy (RAST)™, which allows physicians to treat various diseases without ever entering the body, providing continuous real-time visualization throughout the procedure. The company's initial focus is in interventional oncology, including the treatment of liver, kidney and pancreatic cancer and has vison to apply the technology in the future to lung, breast, thyroid and brain cancers. Commercialization in the US and EU is planned for later this year.
"It's an honor to be recognized by a national publication as one of the most exciting companies in health technology," said Mike Blue, the CEO of HistoSonics. "We believe RAST offers a truly revolutionary way to eliminate diseased tissue from the body. Our mission is to build a new platform in cancer care that is better for patients, and we are doing this by developing a completely non-invasive robot that uses sensing technology to deliver personalized treatments, without the use of ionizing radiation, the need to burn tissue, or ever entering the patient's body. Our platform is unique in that it can accurately destroy targeted diseased tissues without damaging surrounding tissue or critical structures, potentially avoiding challenging complications associated with traditional therapies, and will provide significant advantages to both patients and physicians."
Read the full article from The Observer (titled "'Flyover Tech' Is All the Rage at the 2019 J.P. Morgan Healthcare Investment Conference").
HistoSonics is a venture-backed medical device company whose mission is to redefine cancer treatment with a non-invasive, highly precise, cost-effective method of tumor destruction called Robotically Assisted Sonic Therapy (RAST). The team at HistoSonics is currently developing a completely non-invasive robot that has the potential to deliver personalized treatments over a broad range of cancers in an outpatient setting, without the incisions, punctures, pain, scarring, and long recovery times associated with existing methods of cancer treatment. RAST is based on the science of histotripsy, a non-invasive ablation modality that uses the pressure created by focused sound energy to completely destroy tissue at a sub-cellular level. HistoSonics is represented by a team of experienced specialists and industry leaders with offices in Ann Arbor, Michigan, and Minneapolis, Minnesota.
HistoSonics, Inc. has raised $33 million to date and expects to enter select markets late in 2019.
For more information please visit: http://www.histosonics.com.
SOURCE HistoSonics, Inc.